Bio Pharma Dive
NOVEMBER 7, 2022
Buoyed by strong mid-stage study results, the biotech will soon start a cardiovascular outcomes trial of a drug designed to target a genetic risk factor called lipoprotein(a).
Drug Discovery World
NOVEMBER 7, 2022
In 2018, the UK’s department of health announced an NHS Genomic Medicine Service, which allows patients with rare diseases to have their entire genetic code read in the hope of providing a much-needed diagnosis. That said, some people with rare genetic diseases remain without a molecular diagnosis after their genome is analysed. . “We
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MAY 21, 2024
In contrast, machine learning can facilitate epitope-specific design: directing the algorithm towards favourable epitopes that elicit favourable biological responses, which may improve the prospects for the antibody in drug trials. These targets, along with many others, are universally deemed as ‘difficult-to-drug’ targets.
pharmaphorum
AUGUST 25, 2022
Obesity, diabetes, and genetics are the primary drivers, and COVID is about to make this exponentially worse. But herein lies the dichotomy that medicine has created: By failing to regularly screen to find the early-stage disease, the number of patients who could participate in drug trials is limited.
Drug Discovery World
FEBRUARY 20, 2023
The approval was based on results from the PROpel Phase III trial, however, the drug was rejected by UK regulator NICE because it requires expensive genetic testing. The post What are the top disease areas for clinical drug trials? appeared first on Drug Discovery World (DDW).
XTalks
SEPTEMBER 11, 2020
A study published in JAMA Oncology found that in cancer drug trials conducted between 2008 and 2018, nearly two-thirds of participants were non-Hispanic whites. When trial populations don’t match the broader patient base, the treatments they produce aren’t as effective. Nearly all diseases have a genetic component.
XTalks
MAY 16, 2023
The exact cause of pulmonary fibrosis is often unknown, and in such cases, it is referred to as idiopathic pulmonary fibrosis (IPF); however, certain factors can contribute to the development of pulmonary fibrosis, including environmental and occupational exposures, certain medications, autoimmune diseases and genetic predisposition.
Expert insights. Personalized for you.
288 
Let's personalize your content